Skip to main content
Smart Investors Daily
AR

NASDAQ · ARGX

argenx SE

Healthcare · Biotechnology

$941.25

Up+$0.79 (+0.08%)

Updated Nov 20, 2026, 1:56 AM

SID Score

5.9/10

Composite research score

Smart Money

56/100

Neutral

Market cap
47.46B
P/E ratio
42.26
Dividend yield
0.00%
52-week range
$661.85 – $1,072.75
Volume
309.89K
Avg. volume
347.54K

Price performance · ARGX

ARGX price history

1M range · 0 trading sessions · Daily adjusted prices

ARGX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARGX news

The latest Smart Investors Daily articles mentioning ARGX.

ARGX research

Overview

Company profile and research snapshot.

Company profile

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$967.36
Implied upside
—
Analysts
10
ARGX recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 22, 2026BNP PARIBASOutperform—
Sep 22, 2026TD COWENBuy—
Sep 21, 2026DAY BY DAYBuy—
Sep 14, 2026KBC SECURITIESBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal

argenx has delivered strong share price gains in recent years, so the immediate question for investors is whether today’s valuation can be explained by the company’s earnings power. With sentiment also shaped by fresh clinical and deal news, the current price invites a closer look at what the profit profile really supports. Over the past 5 years argenx has returned 227.0%. That puts real weight on whether the profit stream behind the stock can carry that kind of move. The planned acquisition...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.